Retatrutide, an investigational drug for obesity that has not been approved by the U.S. Food and Drug Administration (FDA), is being illegally sold online and through medical spas, according to a new statement from the Center for Medicine in the Public Interest (CMPI). The organization warns that consumers are being deceived into purchasing unapproved, potentially dangerous products, and criticizes the FDA for failing to take aggressive enforcement action.
Retatrutide is currently being studied in clinical trials for the treatment of obesity, but it has not received FDA approval and cannot be lawfully sold in the United States. Despite this, sellers are aggressively marketing it as an equivalent or even superior alternative to approved therapies. The CMPI highlights that these illegal products are sourced from unregistered foreign manufacturers with no guarantee of sterility, potency, or ingredient authenticity. Distributors face no accountability, and consumers have no way to know what they are actually injecting.
The consequences are already evident, with documented reports of hospitalizations for acute kidney damage and severe gastrointestinal distress. One 42-year-old woman was rushed to the emergency room after experiencing severe symptoms from black market retatrutide she purchased online. Poison center reports have surged dramatically, with hundreds of reports logged in the first four months of 2026 alone.
The CMPI’s president, Peter Pitts, criticizes the FDA’s response as insufficient: “Warning letters do not shut down black markets. Arrests and seizures do.” He argues that the FDA’s reliance on warning letters without follow-up is less than a slap on the wrist and sends a message that there is no cop on the beat. This inaction allows the illegal market to become more entrenched and normalized, making future enforcement even harder.
Pitts emphasizes that clinical trials exist because consumer demand is not a substitute for scientific evidence. Allowing investigational peptides to become internet lifestyle products before FDA review and approval is not the democratization of medicine, but the degradation of it. He calls for the FDA to coordinate with the Department of Justice, Customs and Border Protection, and the Federal Trade Commission to pursue seizures, injunctions, and criminal referrals against sellers and platforms facilitating this illegal trade.
The broader threat, according to Pitts, is institutional. Every day the market operates without aggressive enforcement, it becomes more difficult to unwind. The FDA must act now, before the window closes to rein in this new frontier for illegal drugs in the digital age.
